Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA–restricted, genetically unmodified allogeneic T cells. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback